B · Normal
[Guangshengtang: Hepatitis B triple all-oral regimen completes phase II clinical trial enrollment] On November 12, Guangshengtang (300436.SZ) announced that the GST-Peak-Triple triple all-oral limited treatment regimen under development by Guangsheng Zhonglin, the company’s innovative drug holding subsidiary, has completed the enrollment of all participants in the six-month phase II clinical trial, with a total of 176 cases enrolled. This program aims to evaluate the functional cure of chronic hepatitis B patients with combination therapy, and related drugs have been included in the list of breakthrough therapies.
A-share announcement express 🕐 2026-11-12 16:04
#clinical trial #EA #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Yonggui Electric: Its holding subsidiary won the bid for a 21.45 million yuan p 11-12 16:14 [Etek: Plans to repurchase the company's shares for 30 million to 50 million yua 11-12 15:58 [Anji Technology: ChinaAMC SSE Science and Technology Innovation Board Semicondu 11-12 15:51 [Yitian Intelligence: Subsidiary computing resource service contract amount adju 11-12 15:49 [Keboda: Chairman proposes to repurchase shares of 150 million to 250 million yu 11-12 15:43 [Sinovac: Category 1 new drug imidosifor for injection approved for marketing] O 11-12 15:33

Comments

0/500
Captcha (click to refresh)
No comments yet